Mu Haiyu, Shen Chunyan, Feng Yiling
Cancer center, The affiliated hospitalof Armed Police for Medical College, Tianjin 300162, China.
Zhongguo Fei Ai Za Zhi. 2009 Jul 20;12(7):780-4. doi: 10.3779/j.issn.1009-3419.2009.07.007.
The chemotherapy of advanced non-small cell lung cancer is in a Bottleneck. The target therapy of Anti-angiogenesis gradually shows an advantage in the therapy of patients with advanced NSCLC. To investigate the short-term efficacy, safety and the quality of life of the target therapy of rh-Endostin combined with chemotherapy in patients with advanced NSCLC.
Sixty-two advanced NSCLC patients were randomly divided into either the trial group with chemotherapy plus rh-Endostin or control group with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria.
The trial groups efficiency rate was 46.87%, while the control group was 26.66%, there was no significant differences of two groups (Chi-square=1.912, P=0.166). The clinical benefit rate was 81.25% in the trial group and 53.33% in control group. There was significant difference of the clinical benefit rate between the trial group and the control group (Chi-square=4.3185, P=0.0377). The score of quality of life in the trial group was significantly higher than that the control group after the treatment (Chi-square=11.233, P=0.0008). There was no significant difference of incidence of toxicities between the trial group and the control group (P>0.05).
Rh-Endostin combined with chemotherapy was effective, reasonable, safe and well tolerated for advanced NSCLC.
晚期非小细胞肺癌的化疗处于瓶颈阶段。抗血管生成靶向治疗在晚期非小细胞肺癌患者的治疗中逐渐显示出优势。探讨重组人血管内皮抑素联合化疗的靶向治疗对晚期非小细胞肺癌患者的短期疗效、安全性及生活质量。
将62例晚期非小细胞肺癌患者随机分为化疗联合重组人血管内皮抑素的试验组和单纯化疗的对照组。2个周期后根据RECIST标准评估疗效和毒性。
试验组有效率为46.87%，对照组为26.66%，两组差异无统计学意义（卡方=1.912，P=0.166）。试验组临床受益率为81.25%，对照组为53.33%。试验组与对照组临床受益率差异有统计学意义（卡方=4.3185，P=0.0377）。治疗后试验组生活质量评分显著高于对照组（卡方=11.233，P=0.0008）。试验组与对照组毒性发生率差异无统计学意义（P>0.05）。
重组人血管内皮抑素联合化疗对晚期非小细胞肺癌有效、合理、安全且耐受性良好。
